Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma
Journal
Clinical Cancer Research
Journal Volume
19
Journal Issue
5
Pages
1257-1268
Date Issued
2013
Author(s)
Angevin E.
Lopez-Martin J.A.
Gschwend J.E.
Harzstark A.
Castellano D.
Soria J.-C.
Sen P.
Chang J.
Shi M.
Kay A.
Escudier B.
Type
journal article